BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Miri AH, Kamankesh M, Llopis-lorente A, Liu C, Wacker MG, Haririan I, Asadzadeh Aghdaei H, Hamblin MR, Yadegar A, Rad-malekshahi M, Zali MR. The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications. Front Pharmacol 2022;13:917184. [DOI: 10.3389/fphar.2022.917184] [Reference Citation Analysis]
2 Direito R, Rocha J, Sepodes B, Eduardo-Figueira M. From Diospyros kaki L. (Persimmon) Phytochemical Profile and Health Impact to New Product Perspectives and Waste Valorization. Nutrients 2021;13:3283. [PMID: 34579162 DOI: 10.3390/nu13093283] [Reference Citation Analysis]
3 Chen P, Liu J, Zhang K, Huang D, Huang S, Xie Q, Yang F, Huang J, Fang D, Huang Z, Lu Z, Chen Y. Preparation of clarithromycin floating core-shell systems (CSS) using multi-nozzle semi-solid extrusion-based 3D printing. Int J Pharm 2021;605:120837. [PMID: 34197910 DOI: 10.1016/j.ijpharm.2021.120837] [Reference Citation Analysis]
4 Muñoz AB, Stepanian J, Trespalacios AA, Vale FF. Bacteriophages of Helicobacter pylori. Front Microbiol 2020;11:549084. [PMID: 33281754 DOI: 10.3389/fmicb.2020.549084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Das S, Das MK, Das R, Gehlot V, Mahant S, Mazumder PM, Das S, Falls N, Kumar V. Isolation, characterization of Berberine from Berberis aristata DC for eradication of resistant Helicobacter pylori. Biocatalysis and Agricultural Biotechnology 2020;26:101622. [DOI: 10.1016/j.bcab.2020.101622] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Medina-ramírez IE, Díaz de León-macias CE, Pedroza-herrera G, Gonzáles-segovia R, Zapien JA, Rodríguez-lópez JL. Evaluation of the biocompatibility and growth inhibition of bacterial biofilms by ZnO, Fe3O4 and ZnO@Fe3O4 photocatalytic magnetic materials. Ceramics International 2020;46:8979-94. [DOI: 10.1016/j.ceramint.2019.12.145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Li B, Lan X, Wang L, Zhao J, Ding J, Ding H, Lei J, Wei Y, Zhang W. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis. Microb Pathog 2020;142:104075. [PMID: 32074497 DOI: 10.1016/j.micpath.2020.104075] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Périco LL, Emílio-Silva MT, Ohara R, Rodrigues VP, Bueno G, Barbosa-Filho JM, Rocha LRMD, Batista LM, Hiruma-Lima CA. Systematic Analysis of Monoterpenes: Advances and Challenges in the Treatment of Peptic Ulcer Diseases. Biomolecules 2020;10:E265. [PMID: 32050614 DOI: 10.3390/biom10020265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
9 Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy.Int J Mol Sci. 2020;21. [PMID: 32046317 DOI: 10.3390/ijms21031136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
10 Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in Helicobacter pylori: current state and future directions. Expert Rev Clin Pharmacol. 2019;12:909-915. [PMID: 31424296 DOI: 10.1080/17512433.2019.1654858] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
11 Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infect Dis 2019;19:447. [PMID: 31113384 DOI: 10.1186/s12879-019-4085-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
12 Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14396. [PMID: 30762742 DOI: 10.1097/md.0000000000014396] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 6.7] [Reference Citation Analysis]
13 Saravanakumar K, Chellia R, Hu X, Kathiresan K, Oh D, Wang M. Eradication of Helicobacter pylori through the inhibition of urease and peptide deformylase: Computational and biological studies. Microbial Pathogenesis 2019;128:236-44. [DOI: 10.1016/j.micpath.2019.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
14 Talebi Bezmin Abadi A, Yamaoka Y. Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 2018;14:111-7. [DOI: 10.1016/j.jgar.2018.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
15 Talebi Bezmin Abadi A, Yamaoka Y. Call for shift in Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 2018;30:687. [PMID: 29697524 DOI: 10.1097/MEG.0000000000001096] [Reference Citation Analysis]
16 Tarhini M, Fayyad-kazan M, Fayyad-kazan H, Mokbel M, Nasreddine M, Badran B, Kchour G. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. Microbial Pathogenesis 2018;117:23-6. [DOI: 10.1016/j.micpath.2018.02.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
17 Abadi ATB. Clarithromycin-based therapy of Helicobacter pylori in Iran. J Glob Antimicrob Resist 2017;11:39. [PMID: 28882764 DOI: 10.1016/j.jgar.2017.08.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
18 Abadi ATB. Strategies used by helicobacter pylori to establish persistent infection. World J Gastroenterol 2017; 23(16): 2870-2882 [PMID: 28522905 DOI: 10.3748/wjg.v23.i16.2870] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 45] [Article Influence: 10.4] [Reference Citation Analysis]